eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2019
vol. 15
 
Share:
Share:
more
 
 
Basic research

Phenotypic identification of CD19+CD5+CD1d+ regulatory B cells that produce interleukin 10 and transforming growth factor β1 in human peripheral blood

Md Rezaul Karim
,
Yun-Fu Wang

Arch Med Sci 2019; 15 (5): 1176–1183
Online publish date: 2018/08/27
Article file
- phenotypic.pdf  [0.43 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

B cells are white blood cells (WBCs) in vertebrates. B cells mature in the bone marrow [1] and are a critical element of the acquired immune system. B-cell maturation in the bone marrow is a dynamic and compound procedure involving a steady balance between cell proliferation and apoptotic selection. Due to this balance in the generation of functioning B cells that are liable for eliciting humoral immunity [2–5]. B cells are well recognised to organise immunological responses by antibody production, which represents the humoral arm of the acquired immune system. B cells are the first facilitators of antigen-specific immunological responses by producing antibodies and differentiating into memory cells that give long-standing immunity [6]. B cells positively modulate immunological responses and inflammation by antibody production and antigen presentation for optimal CD4+ T-cell activation [7, 8]. The antibody production enables optimal CD41 T-cell activation as B cells act as antigen-presenting cells and exert different regulatory roles in immunological responses. Nevertheless, specific B cells also negatively modulate the immunological responses through the production of modulatory cytokines and primarily interact with pathogenic T cells via cell-to-cell communication. These categories of B cells are termed “Bregs” [5]. Over the past decade, the functions of
Bregs in repressing pathological immunological responses have been recognised extensively. In recent years, various studies in both mice and humans have established that Bregs repress inflammatory responses, predominantly through the secretion of interleukin 10 (IL-10) [9]. The regulatory influences of Bregs have been reported in numerous models of autoimmune diseases, inflammation, transplantation reactions, and anti-tumour immunity. Bregs can originate from a distinct B cell subpopulation [10]. Bregs have been determined to act as a suppressive function in the immune system. Bregs can inhibit other immune cells through cytokine production and antigen presentation, which gives them a function in the pathogenesis of cancers and autoimmune diseases [11]. Analysing the B cell subpopulation is a significant area of research due to its therapeutic relevance and role in the immunological response.

Bregs: evidence and origin

The concept of Bregs and a B-cell suppressive event was first noted in 1974, during delayed-type hypersensitivity reactions in guinea pigs [12, 13]. However, it took two decades until the concept of “suppressor B cells” received attention again. Added proof of this B cell modulatory phenotype was evaluated in 1996, which was observed in a murine autoimmune model of experimental autoimmune encephalitis (EAE) where the deficiency of B cells aggravated the inflammation [14]. Then in 1997, it was observed in chronic colitis where the disease worsened in the B-cell deficiency group, suggesting their repressive role in inflammation [15]. The presence of regulatory B cells (Bregs) was confirmed afterwards in 2000 using the term “regulatory B cell”, which described its repressive capability in inflammatory bowel disease [16]. Bregs were reintroduced as an IL-10-producing B cell subpopulation in 2002 [17]. Many attempts have been made in several studies, including mice [18–34] and humans [26, 35–38], at phenotypic identification and characterisation.

Significance statement

Bregs are critical in maintaining self-tolerance [39]. The essentiality of human Bregs in the upholding of immune homeostasis originates from various immune-associated pathologies, such as cancers, autoimmune diseases, and chronic infections that are frequently related to abnormalities in Breg numbers or function [40].
Moreover, to be more specific clinically, such as the role of Bregs in autoimmunity, defects in numbers and functions have been reported in multiple autoimmune diseases, including multiple sclerosis (MS), myasthenia gravis (MG), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and psoriasis [35, 41–45]. Inverse correlations were found between Breg numbers and functions, and disease severity status measured using severity scales, e.g, the Multiple Sclerosis Severity Score (MSSS), the Quantitative Myasthenia Gravis score (QMG), the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), the Rheumatoid Arthritis Severity Scale (RASS), the Psoriasis Area and Severity Index (PASI), etc. These inverse correlations may be due to the loss of immune suppression precipitated by Bregs, giving rise to inflammation, or the reduced Breg numbers and function are a consequence of chronic inflammation. Even though a modulatory function of B cells is well established, more research is required to learn more about their phenotypic identification and characterisation [46]. Knowing the roles of B cells and having the capability to trace an increase or decrease in B cell subpopulation levels can anticipate a useful method for understanding the immunological responses to certain diseases [47]. A constant attempt to perceive Breg biology in healthy controls will yield new possibilities to establish Breg immunotherapy [40].
B cells play a pivotal role in several autoimmune diseases, including patients with MS [48]. Therapeutic interventions targeting B cells have been a useful approach in MS, such as total B cell depletion therapy. The studies describing total B cell depletion therapy using ocrelizumab and rituximab have proven the clinical efficacy in MS [49–51]. B cell depletion might be improved for the treatment of MS, through an approach to deplete subsets of B cells selectively [52], such as in vivo depletion of Bregs. Specific subsets of B cells would give increased advantages over current total B cell depletion therapies [40]. Other therapeutic interventions target Bregs to develop Breg immunotherapy in MS, by B cell isolation of patient-derived PBMCs and in vitro Breg expansion, then adoptive transfer into the patient could suppress inflammation, or in vivo modulation to expand Bregs [40]. These could offer advanced perspectives for therapy of patients with MS.

Material and methods

Materials and equipment

Blood sample with anticoagulation (heparin), Ficoll, phosphate buffered saline (PBS), buffer (ultra-pure water – 1000 ml, NaCl – 8 g, KCl – 0.2 g, Na2HPO4 × 12 H2O – 3.58 g, KH2PO4 – 0.27 g, EDTA – 0.74 g, 0.5% BSA – 5 g), fetal bovine serum (FBS), RPMI-1640 medium, 1% penicillin/streptomycin/amphotericin B mixture, B cell isolation kit II, MS column and miniMACS separator, human IL-10 and TGF-1 ELISA kit, standard ELISA microplate reader, PerCP CD19, FITC CD5 and PE CD1d antibodies, flow cytometer, water bath (37ºC), refrigerator, cell culture flasks, and dishes, centrifuges, centrifuge tubes, pipettes, haemocytometer.

Ethical consideration and approval, informed consent

The research was performed with the approval of the institutional review board (IRB) of the Hubei University of Medicine, Shiyan, Hubei 442000, China; and the project was evaluated and approved by the assessment panel. The purpose of this research was explained to the participants, and when the oral consent was understood and agreed, in front of a nurse, a consent form was provided in English and Chinese. This process was done to obtain the informed consent as well as the legal identification. The individuals who gave consent were included in the project.

Data collection

We involved all participants from Taihe Hospital of Hubei University of Medicine. We obtained 20 ml blood samples from 40 healthy controls, aged between 18 and 55 years of age. These participants did not receive any medication for cancers or autoimmune diseases.

Preparation and storage of PBMCs

First of all, a human peripheral blood sample was obtained in 20 ml disposable syringes and anticoagulation (heparin) was added. It was then gently diluted in PBS (Good Bio, China) and peripheral blood mononuclear cells (PBMCs) were isolated through Ficoll (TBD Sciences, China) gradient centrifugation based on the manufacturer’s protocol. A culture medium (RPMI-1640 medium + 10% FBS + 1% penicillin/streptomycin/amphotericin B mixture) was added, and then the sample was transferred to two different cell culture flasks using a pipette. Flask 1 was used for isolation and storage of B cells, and flask 2 was used for flow cytometric analysis of PBMCs.

Isolation and storage of B cells

After centrifugation, supernatant was discarded, and cell numbers (PBMCs) were determined using a haemocytometer. Then the B cells were isolated through magnetic separation based on the manufacturer’s protocol utilising an MS column and B cell isolation kit II (Miltenyi Biotec, USA). A culture medium (RPMI-1640 medium + 10% FBS + 1% penicillin/streptomycin/amphotericin B mixture) was added and then transferred to a cell culture flask using a pipette. The flask was used for flow cytometric analysis of B cells and ELISA assays.

Cell staining and flow cytometric analysis

After centrifugation, supernatant was discarded, and cell numbers (PBMCs or B cells) were determined using a haemocytometer. Then the cells were resuspended in buffer and cells were surface stained with CD19, CD5, and CD1d antibodies (BD Biosciences, USA). The cells were then incubated in a refrigerator at 4°C for 30 min, followed by two washing steps to remove any residual antibody from the cell suspension. The samples were interpreted using the flow cytometer BD FACSCanto II (BD Biosciences, USA), and the data were analysed by BD FACSDiva 8.0.1 software.

ELISA

Enzyme-linked immunosorbent assay (ELISA) was performed using a human IL-10 and TGF-1 ELISA kit (Neobioscience, China) based on the manufacturer’s protocol. The absorbency was assessed by a microplate reader (Thermo Scientific, Finland). After completing the experiments, remaining reagents were put back in a refrigerator for temperature restoration.

Statistical analysis

Data were analysed using descriptive statistics in SPSS V25.0 and shown as mean ± SD.

Results

Phenotypic Identification of CD19+CD5+CD1d+ Bregs

The CD19+CD5+CD1d+ Bregs were phenotypically identified using specific CD markers: CD19, CD5, CD1d which are the key markers for identifying Bregs [17, 41, 53–56]. Breg cell subpopulations were identified by double positive staining of CD5+CD1d+ Bregs from PBMCs and B cells (Figure 1). This novel CD19+CD5+CD1d+ Breg subpopulation in human peripheral blood was represented (n = 40; 19.27 ±1.52) from PBMCs (n = 40; 33.32 ±2.95) from isolated B cells accordingly. These mean values of Bregs identified here can be referred to as the normal ranges that are responsible for maintaining a dynamic balance through a certain level in healthy controls. Any alterations to the mean values may indicate marked defects.

Characterisation of phenotypically identified CD19+CD5+CD1d+ Bregs

The characterisation of phenotypically identified CD19+CD5+CD1d+ Bregs was observed through ELISA assays using human IL-10 and TGF-1 ELISA kits based on the manufacturer’s protocol. The IL-10 production represents (n = 40; 0.56 ±0.08), and TGF-1 production represents (n = 40; 0.90 ±0.12) by these phenotypically identified CD19+CD5+CD1d+ Bregs.. These mean values of cytokine production can be referred to as the functional properties of Bregs when maintaining a dynamic balance through a certain level in healthy controls. Alterations may disrupt the normal regulatory function.

Discussion

During immunoreaction, B cells manifested positive and negative modulatory influences [57]. The modulatory function of B cells in autoimmune diseases was demonstrated in 1996 in EAE [58]. Bregs’ (B10 cells) existence was confirmed after that by others [58, 59]; B cell subpopulations were found to be capable of influencing immunological tolerance [22, 28, 57, 58, 60, 61]. Bregs expressed a reduced and impaired role in most of the studies. The term “Bregs” was introduced by Matsushita, who established Bregs as an IL-10 secreting B cell subpopulation in 2002 [62]. Bregs carried out diverse mechanisms to regulate immunological responses and aimed for numerous unique immune cell types, such as DCs [63] and macrophages [64] as well as T helper (Th1 and Th2) cells [65]. It was found that Bregs were effective in repressing the expansion of CD4+CD25– T cells [66]. According to the present state of affairs concerning the phenotypes and markers of human Bregs [17, 67–70], they exhibit some of the same phenotypic properties as formerly defined markers in mice [35, 37]. In this study, we phenotypically identified Bregs using specific CD markers by double positive staining of CD5+CD1d+ Bregs in human peripheral blood. In most of the previous studies, Bregs were identified from PBMCs [17, 26, 35–38, 40–45, 53–56, 67–72]. In this study, we used both techniques which include Breg identification from PBMCs and isolated B cells. We observed that the percentage of Bregs was higher if identified from isolated B cells than from PBMCs. Therefore, the identification of isolated B cells provides greater specificity.
Nonetheless, of the variety of markers used to identify Bregs, the protective effects of Bregs are dependent on IL-10 [17, 37, 71, 72], a potent deactivator which limits the potency and time of inflammatory responses. Consequently, IL-10 secretion is still an essential criterion in the identification of Bregs. The leading role of IL-10 is to repress excessive inflammation and control homeostasis via various mechanisms.
This mechanism involves hindering antigen presentation and co-stimulatory molecules CD80, CD86, and MHC class II expression through DCs and macrophages. The suppression of excessive inflammation and maintenance of homeostasis can also be regulated by inhibiting cytokine release by T cells in immunological responses and supporting Treg differentiation [73]. While IL-10 secretion remains the hallmark of Bregs’ negative modulatory role, other independent repressive mechanisms, e.g. involving TGF-1, have been revealed in recent years. Secretion of TGF-1 by B cells give rise to the support of Treg development in transplant tolerance, diabetes, allergic diseases, and colitis [74]. In this study, we also observed, through ELISA assays, that these novel CD19+CD5+CD1d+ Bregs produce anti-inflammatory cytokines IL-10 and TGF-1 (see Figure 2 for Breg cell phenotype and character diagram based on the current state of knowledge and this study).
Interestingly, recent research suggests that Bregs can also directly approach the central nervous system (CNS) [31]. In addition, people living with type 1 diabetes express the lowest frequency of B10 cells in comparison with type 2 diabetes, adult latent autoimmune diabetes, and controls [75]. In SLE, Bregs are emerging as an essential player at the time of disease instigation. Adoptive shifting of splenic CD5+CD1dhi Bregs from wild-type mice expanded the time of endurance of CD19–/–mice in this lupus model [76]. In humans, SLE patients showed indistinguishable frequencies of circulating CD24hiCD38hi B cells, but had a remarkably lower IL-10+ proportion in comparison with controls [77]. Rheumatoid arthritis studies have also implied that Bregs are responsible for Tregs’ initial inducement [78]. In one of our recent studies, we identified a lower frequency of CD19+CD5+CD1d+ Bregs in MG and lower cytokine secretion compared to healthy controls. Based on QMG scoring techniques we have also observed that the lower the cytokine levels are, the more clinical symptoms the patient has [41]. Thus, the detailed protocol and methods presented here are extremely valuable and should be able to facilitate progress in research on various autoimmune diseases, cancer, inflammation, and immunologic responses.
In conclusion, Bregs are a significant area of research due to their immune regulatory function in the immunological responses through their potential cytokine production. Through flow cytometric analysis and ELISA assays of B cells of the human peripheral blood sample, either from PBMCs or isolated B cells, the regulatory role may be observed. The healthy controls can be compared with particular autoimmune diseases, inflammation, cancer, and immunologic responses to find out whether Breg alteration and/or cytokine production is altered in these disorders or conditions. If the alteration of Bregs and cytokine production is significant along with the clinical correlation, a further in vitro study can be conducted such as PBMC or B cell culture with exposure to certain drugs. If cytokine production improves, then an in vivo study can be initiated. ,

Acknowledgments

The authors thank Dr Afsarunnesa Syeda from Renmin Hospital of Hubei University of Medicine, China, for all the support; and appreciate the help of Ms Helia Garcia from Wright State University, USA for proofreading this work.
The study was supported by the national natural science foundation of China (no. 81671238).

Conflict of interest

The authors declare no conflict of interest.

References

1. Cooper MD. The early history of B cells. Nature Rev Immunol 2015; 15: 191-7.
2. Osmond DG. B cell development in the bone marrow. Semin Immunol 1990; 2: 173-80.
3. Cooper MD. Exploring lymphocyte differentiation pathways. Immunol Rev 2002; 185: 175-85.
4. Welner RS, Pelayo R, Kincade PW. Evolving views on the genealogy of B cells. Nature Rev Immunol 2008; 8: 95-106.
5. Yang M, Rui K, Wang S, Lu L. Regulatory B cells in autoimmune diseases. Cell Mol Immunol 2013; 10: 122-32.
6. Guzman-Genuino RM, Diener KR. Regulatory B cells in pregnancy: lessons from autoimmunity, graft tolerance, and cancer. Front Immunol 2017; 8: 172.
7. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008; 112: 1570-80.
8. Tedder TF. Introduction: regulatory B cell special issue – making all the pieces fit. Int Immunol 2015; 27: 467-70.
9. Mauri C, Bosma A. Immune regulatory function of B cells. Ann Rev Immunol 2012; 30: 221-41.
10. Vitale G, Mion F, Pucillo C. Regulatory B cells: evidence, developmental origin and population diversity. Mol Immunol 2010; 48: 1-8.
11. He Y, Qian H, Liu Y, Duan L, Li Y, Shi G. The roles of regulatory B cells in cancer. J Immunol Res 2014; 2014, 215471.
12. Katz SI, Parker D, Turk JL. B-cell suppression of delayed hypersensitivity reactions. Nature 1974; 251: 550-1.
13. Neta R, Salvin SB. Specific suppression of delayed hypersensitivity: the possible presence of a suppressor B cell in the regulation of delayed hypersensitivity. J Immunol 1974; 113: 1716-25.
14. Wolf SD, Dittel BN, Hardardottir F, Janeway CA. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996; 184: 2271-8.
15. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 1997; 186: 1749-56.
16. Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol 2000; 12: 597-605.
17. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002; 16: 219-30.
18. Amu S, Saunders SP, Kronenberg M, Mangan NE, Atzberger A, Fallon PG. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol 2010; 125: 1114-24.e8.
19. Bankoti R, Gupta K, Levchenko A, Stager S. Marginal zone B cells regulate antigen-specific T cell responses during infection. J Immunol 2012; 188: 3961-71.
20. Blair PA, Chavez-Rueda KA, Evans JG, et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol 2009; 182: 3492-502.
21. Evans JG, Chavez-Rueda KA, Eddaoudi A, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007; 178: 7868-78.
22. Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther 2013; 15 (Suppl 1): S1.
23. Khan AR, Amu S, Saunders SP, et al. Ligation of TLR7 on CD19+CD1dhiB cells suppresses allergic lung inflammation via regulatory T cells. Eur J Immunol 2015; 45: 1842-54.
24. Klinker MW, Reed TJ, Fox DA, Lundy SK. Interleukin-5 supports the expansion of Fas ligand-expressing killer B cells that induce antigen-specific apoptosis of CD4+ T cells and secrete interleukin-10. PLoS One 2013; 8: e70131.
25. Liu Z, Wu Y, Song J, et al. Tolerogenic CX3CR1+B cells suppress food allergy-induced intestinal inflammation in mice. Allergy 2013; 68: 1241-8.
26. Matsumoto M, Baba A, Yokota T, et al. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Immunity 2014; 41: 1040-51.
27. Moreau A, Blair PA, Chai J, et al. Transitional-2 B cells acquire regulatory function during tolerance induction and contribute to allograft survival. Eur J Immunol 2014; 45: 843-53.
28. Sheng JR, Quan S, Soliven B. CD1dhiCD5+B cells expanded by GM-CSF in vivo suppress experimental autoimmune myasthenia gravis. J Immunol 2014; 193: 2669-77.
29. Shimomura Y, Mizoguchi E, Sugimoto K, et al. Regulatory role of B-1 B cells in chronic colitis. Int Immunol 2008; 20: 729-37.
30. Watanabe R, Ishiura N, Nakashima H, et al. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol 2010; 184: 4801-9.
31. Yanaba K, Bouaziz J, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1­dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008; 28: 639-50.
32. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Tedder TF, Sato S. IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol 2011; 178: 735-43.
33. Yang M, Deng J, Liu Y, et al. IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation. Am J Pathol 2012; 180: 2375-85.
34. Zhang X, Deriaud E, Jiao X, Braun D, Leclerc C, Lo-Man R. Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J Exp Med 2007; 204: 1107-18.
35. Blair PA, Noreña LY, Flores-Borja F, et al. CD19+CD24hi­CD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32: 129-40.
36. Das A, Ellis G, Pallant C, et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol 2012; 189: 3925-35.
37. Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2010; 117: 530-41.
38. Van de Veen W, Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 2013; 131: 1204-12.
39. Li W, Tian X, Lu X, et al. Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis. Sci Rep 2016; 6: 27479.
40. Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. J Clin Investig 2017; 127: 772-9.
41. Karim MR, Zhang H, Yuan J, Sun Q, Wang Y. Regulatory B cells in seropositive myasthenia gravis versus healthy controls. Front Neurol 2017; 8: 43.
42. Knippenberg S, Peelen E, Smolders J, et al. Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission. J Neuroimmunol 2011; 239: 80-6.
43. Bosma A, Abdel-Gadir A, Isenberg D, Jury E, Mauri C. Lipid-antigen presentation by CD1d+ B cells is essential for the maintenance of invariant natural killer T cells. Immunity 2012; 36: 477-90.
44. Flores-Borja F, Bosma A, Ng D, et al. CD19+CD24hiCD­38hi B cells maintain regulatory T cells while limiting Th1 and Th17 differentiation. Sci Transl Med 2013; 5: 173ra23.
45. Hayashi M, Yanaba K, Umezawa Y, et al. IL-10-producing regulatory B cells are decreased in patients with psoriasis. J Dermatol Sci 2016; 81: 93-100.
46. Ray A, Dittel B. Mechanisms of regulatory B cell function in autoimmune and inflammatory diseases beyond IL-10. J Clin Med 2017; 6: 12.
47. Santos M, Zhang W, White L, Whalley J, Hsu M. Überwachung von DNA-schäden an kontrollpunkten des zellzyklus. BIOspektrum 2011; 17: 200-2.
48. Memon AB, Javed A, Caon C, et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One 2018; 13: e0190425.
49. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376: 221-34.
50. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-88.
51. Ellwardt E, Ellwardt L, Bittner S, Zipp F. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol Neuroimmunol Neuroinflamm 2018; 5: e463.
52. Clark EA. How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis 2005; 64 (Suppl 4): iv77-80.
53. Habib J, Deng J, Lava N, Tyor W, Galipaeu J. Blood B cell and regulatory subset content in multiple sclerosis patients. J Mult Scler 2015; 2: pii: 1000139.
54. Zhang M, Zeng G, Yang Q, et al. Anti-tuberculosis treatment enhances the production of IL-22 through reducing the frequencies of regulatory B cell. Tuberculosis 2014; 94: 238-44.
55. Zhang M, Zheng X, Zhang J, et al. CD19+CD1d+CD5+ B cell frequencies are increased in patients with tuberculosis and suppress Th17 responses. Cell Immunol 2012; 274: 89-97.
56. Zhang L, Sun X. The expression and effect of helper IL-10- producing B cells in human minimal change nephrotic syndrome. Ann Clin Labor Res 2016; 4. doi: 10.21767/2386-5180.100079.
57. Airoldi I. Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes. Clin Cancer Res 2004; 10: 144-54.
58. Lang ML. How do natural killer T cells help B cells? Exp Rev Vaccines 2009; 8: 1109-21.
59. Benson M, Erickson L, Gleeson M, Noelle R. Affinity of antigen encounter and other early B-cell signals determine B-cell fate. Curr Opin Immunol 2007; 19: 275-80.
60. Watkins NA, Gusnanto A, De Bono B, et al. A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood 2009; 113: e1-9.
61. Novershtern N, Subramanian A, Lawton LN, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 2011; 144: 296-309.
62. Matsushita T. Regulatory B cell and autoimmune disease. Japan J Clin Immunol 2010; 33: 234-41.
63. DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immunologic-responses during inflammation, autoimmunity, and cancer. Ann N York Acad Sci 2010; 1183: 38-57.
64. Lehmann-Horn K, Kronsbein HC, Weber MS. Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neurol Disord 2013; 6: 161-73.
65. Jensen F, Muzzio D, Soldati R, Fest S, Zenclussen AC. Regulatory B10 cells restore pregnancy tolerance in a mouse model1. Biol Reprod 2013; 89: 1-7.
66. Giannoukakis N, Trucco M. A role for tolerogenic dendritic cell-induced B-regulatory cells in type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2012; 19: 279-87.
67. Matsushita T, Horikawa M, Iwata Y, Tedder TF. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol 2010; 185: 2240-52.
68. Wong S, Puaux A, Chittezhath M, et al. Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol 2010; 40: 2296-307.
69. Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167: 1081-9.
70. Liu Y, Chen Y, Li Z, et al. Role of IL-10-producing regulatory B cells in control of cerebral malaria in plasmodium berghei infected mice. Eur J Immunol 2013; 43: 2907-18.
71. Furuzawa-Carballeda J, Hernández-Molina G, Lima G, Rivera-Vicencio Y, Férez-Blando K, Llorente L. Peripheral regulatory cells immunophenotyping in primary Sjögren’s syndrome: a cross-sectional study. Arthritis Res Ther 2013; 15: R68.
72. Daien CI, Gailhac S, Mura T, et al. Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity. Arthritis Rheumatol 2014; 66: 2037-46.
73. Wang L, Qiu J, Yu L, Hu X, Zhao P, Jiang Y. Increased numbers of CD5+CD19+CD1dhighIL-10+ Bregs, CD4+Foxp3+ Tregs, CD4+CXCR5+Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients. J Transl Med 2014; 12: 251.
74. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol 2008; 64: 187-99.
75. Matsushita T, Yanaba K, Bouaziz J, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118: 3420-30.
76. Byrne SN, Halliday GM. B cells activated in lymph nodes in response to ultraviolet irradiation or by interleukin-10 inhibit dendritic cell induction of immunity. J Investig Dermatol 2005; 124: 570-8.
77. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Ann Rev Immunol 2004; 22: 929-79.
78. Ray A, Wang L, Dittel BN. IL-10-independent regulatory B-cell subpopulations and mechanisms of action. Int Immunol 2015; 27: 531-6.
79. Korniotis S, Gras C, Letscher H, et al. Treatment of ongoing autoimmune encephalomyelitis with activated B-cell progenitors maturing into regulatory B cells. Nat Commun 2016; 7: 12134.
80. Deng C, Xiang Y, Tan T, et al. Altered peripheral B-lymphocyte subpopulations in type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care 2015; 39: 434-40.
81. Heinemann K, Wilde B, Hoerning A, et al. Decreased IL-10+regulatory B cells (Bregs) in lupus nephritis patients. Scand J Rheumatol 2016; 45: 312-6.
82. Carter NA, Vasconcellos R, Rosser EC, et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 2011; 186: 5569-79.
Copyright: © 2018 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe